7-methoxy-1-(2-morpholinoethyl)-N-((1S4R)-133-trimethylbicyclo[2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (N-[(S)-fenchyl]-1-[2-(morpholin-4-yl)ethyl]-7-methoxyindole-3-carboxamide UR-12 MN-25) is a drug invented by Bristol-Myers Squibb that acts as a reasonably selective agonist of peripheral cannabinoid receptors. It has moderate affinity for CB2 receptors with a Ki of 11nM but 22x lower affinity for the psychoactive CB1 receptors with a Ki of 245nM.
